OraSure Technologies Inc
OSUR2.710USD
-0.020-0.73%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
195.84MValor de mercado
PerdaP/L TTM
Mais detalhes de OraSure Technologies Inc Empresa
OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company improves the access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers. Its products and services include OraQuick ADVANCE Rapid HIV1/2 Antibody Test, OraQuick HIV Self-Test, and Diagnostics Direct Syphilis Health Check.
Informações de OraSure Technologies Inc
Código da empresaOSUR
Nome da EmpresaOraSure Technologies Inc
Data de listagemNov 17, 1986
CEOEglinton Manner (Carrie)
Número de funcionários501
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 17
Endereço220 E First St
CidadeBETHLEHEM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal18015
Telefone15036416115
Sitehttps://www.orasure.com/
Código da empresaOSUR
Data de listagemNov 17, 1986
CEOEglinton Manner (Carrie)
Executivos da empresa OraSure Technologies Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Kenneth J. (Ken) Mcgrath
Mr. Kenneth J. (Ken) Mcgrath
Chief Financial Officer
Chief Financial Officer
448.46K
-12524.00%
Mr. John P. Kenny
Mr. John P. Kenny
Independent Chairman of the Board
Independent Chairman of the Board
163.61K
+10286.00%
Dr. Nancy J. Gagliano, M.D.
Dr. Nancy J. Gagliano, M.D.
Independent Director
Independent Director
160.25K
+2100.00%
Mr. Lelio Marmora
Mr. Lelio Marmora
Independent Director
Independent Director
130.76K
+63040.00%
Hon Dr. David J. Shulkin, M.D.
Hon Dr. David J. Shulkin, M.D.
Independent Director
Independent Director
126.33K
+66018.00%
Ms. Carrie Eglinton Manner
Ms. Carrie Eglinton Manner
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Jason Plagman
Mr. Jason Plagman
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Mr. Robert W. Mcmahon
Mr. Robert W. Mcmahon
Independent Director
Independent Director
--
--
Ms. Anne Messing
Ms. Anne Messing
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Steven K. (Steve) Boyd
Mr. Steven K. (Steve) Boyd
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Kenneth J. (Ken) Mcgrath
Mr. Kenneth J. (Ken) Mcgrath
Chief Financial Officer
Chief Financial Officer
448.46K
-12524.00%
Mr. John P. Kenny
Mr. John P. Kenny
Independent Chairman of the Board
Independent Chairman of the Board
163.61K
+10286.00%
Dr. Nancy J. Gagliano, M.D.
Dr. Nancy J. Gagliano, M.D.
Independent Director
Independent Director
160.25K
+2100.00%
Mr. Lelio Marmora
Mr. Lelio Marmora
Independent Director
Independent Director
130.76K
+63040.00%
Hon Dr. David J. Shulkin, M.D.
Hon Dr. David J. Shulkin, M.D.
Independent Director
Independent Director
126.33K
+66018.00%
Ms. Carrie Eglinton Manner
Ms. Carrie Eglinton Manner
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Net product and services revenues - HIV
14.50M
53.53%
Net product and services revenues - Microbiome
10.31M
38.05%
Other revenues - Other non Product revenues
1.75M
6.46%
Net product and services revenues - Other Products revenue
442.00K
1.63%
Other revenues
442.00K
1.63%
Outro
-353.00K
-1.30%
Por RegiãoUSD
Nome
Receita
Proporção
United States
19.66M
72.59%
Africa (Region)
4.88M
18.00%
Europe
1.30M
4.80%
Other Regions
1.25M
4.61%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Net product and services revenues - HIV
14.50M
53.53%
Net product and services revenues - Microbiome
10.31M
38.05%
Other revenues - Other non Product revenues
1.75M
6.46%
Net product and services revenues - Other Products revenue
442.00K
1.63%
Other revenues
442.00K
1.63%
Outro
-353.00K
-1.30%
Distribuição de ações
Atualizado em: sáb, 15 de nov
Atualizado em: sáb, 15 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
7.81%
Private Management Group, Inc.
7.55%
Neuberger Berman, LLC
5.86%
The Vanguard Group, Inc.
5.72%
Altai Capital Management, L.P.
5.21%
Outro
67.85%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
7.81%
Private Management Group, Inc.
7.55%
Neuberger Berman, LLC
5.86%
The Vanguard Group, Inc.
5.72%
Altai Capital Management, L.P.
5.21%
Outro
67.85%
Tipos de investidores
Investidores
Proporção
Investment Advisor
37.18%
Investment Advisor/Hedge Fund
27.00%
Hedge Fund
23.55%
Individual Investor
6.13%
Research Firm
2.26%
Pension Fund
0.47%
Bank and Trust
0.29%
Venture Capital
0.11%
Family Office
0.01%
Outro
3.00%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
443
65.15M
90.83%
-17.13M
2025Q3
451
66.91M
93.28%
-15.50M
2025Q2
473
72.08M
98.55%
-16.70M
2025Q1
483
70.23M
93.78%
-12.52M
2024Q4
475
70.81M
94.94%
-10.37M
2024Q3
471
70.30M
94.28%
-10.80M
2024Q2
477
73.05M
98.74%
-8.54M
2024Q1
473
74.45M
97.36%
-5.59M
2023Q4
464
73.29M
99.74%
-5.62M
2023Q3
456
72.50M
98.73%
-4.51M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
5.60M
7.81%
+164.29K
+3.02%
Sep 30, 2025
Private Management Group, Inc.
5.42M
7.55%
-44.15K
-0.81%
Sep 30, 2025
Neuberger Berman, LLC
4.20M
5.86%
+46.91K
+1.13%
Sep 30, 2025
The Vanguard Group, Inc.
4.13M
5.76%
-35.41K
-0.85%
Sep 30, 2025
Altai Capital Management, L.P.
3.74M
5.21%
-8.00K
-0.21%
Dec 17, 2025
Dimensional Fund Advisors, L.P.
3.64M
5.07%
-200.81K
-5.23%
Sep 30, 2025
Systematic Financial Management, L.P.
2.52M
3.52%
+293.37K
+13.16%
Sep 30, 2025
Renaissance Technologies LLC
2.26M
3.15%
-15.20K
-0.67%
Sep 30, 2025
Acadian Asset Management LLC
2.12M
2.96%
-67.10K
-3.06%
Sep 30, 2025
Millennium Management LLC
2.11M
2.94%
+878.15K
+71.14%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Invesco NASDAQ Future Gen 200 ETF
0.44%
iShares US Small Cap Value Factor ETF
0.12%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.05%
iShares Micro-Cap ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
Avantis US Small Cap Equity ETF
0.02%
WisdomTree US SmallCap Fund
0.02%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
DFA Dimensional US Small Cap Value ETF
0.01%
Ver Mais
Invesco NASDAQ Future Gen 200 ETF
Proporção0.44%
iShares US Small Cap Value Factor ETF
Proporção0.12%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
Proporção0.05%
iShares Micro-Cap ETF
Proporção0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0.04%
Avantis US Small Cap Equity ETF
Proporção0.02%
WisdomTree US SmallCap Fund
Proporção0.02%
ProShares UltraPro Russell2000
Proporção0.01%
Proshares Ultra Russell 2000
Proporção0.01%
DFA Dimensional US Small Cap Value ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
